MX2023010728A - Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. - Google Patents
Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.Info
- Publication number
- MX2023010728A MX2023010728A MX2023010728A MX2023010728A MX2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A MX 2023010728 A MX2023010728 A MX 2023010728A
- Authority
- MX
- Mexico
- Prior art keywords
- depressive disorder
- major depressive
- subject
- disubstituted
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 208000024714 major depressive disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000011221 initial treatment Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162501P | 2021-03-17 | 2021-03-17 | |
| US202163284592P | 2021-11-30 | 2021-11-30 | |
| PCT/US2022/020716 WO2022197901A1 (en) | 2021-03-17 | 2022-03-17 | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010728A true MX2023010728A (es) | 2024-02-12 |
Family
ID=81327141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010728A MX2023010728A (es) | 2021-03-17 | 2022-03-17 | Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240245711A1 (https=) |
| EP (1) | EP4308162A1 (https=) |
| JP (1) | JP2024510436A (https=) |
| KR (1) | KR20230158033A (https=) |
| AU (1) | AU2022238365A1 (https=) |
| BR (1) | BR112023018607A2 (https=) |
| CA (1) | CA3213744A1 (https=) |
| IL (1) | IL305858A (https=) |
| MX (1) | MX2023010728A (https=) |
| TW (1) | TW202300156A (https=) |
| WO (1) | WO2022197901A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396328B1 (ko) * | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| EP3612186A1 (en) * | 2017-04-18 | 2020-02-26 | Marinus Pharmaceuticals, Inc. | Sustained release injectable neurosteroid formulations |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| US20230372364A1 (en) * | 2020-10-01 | 2023-11-23 | Jeremy Hill | Method of treating gaba mediated disorders |
-
2022
- 2022-03-17 US US18/550,724 patent/US20240245711A1/en active Pending
- 2022-03-17 CA CA3213744A patent/CA3213744A1/en active Pending
- 2022-03-17 BR BR112023018607A patent/BR112023018607A2/pt unknown
- 2022-03-17 MX MX2023010728A patent/MX2023010728A/es unknown
- 2022-03-17 IL IL305858A patent/IL305858A/en unknown
- 2022-03-17 TW TW111109951A patent/TW202300156A/zh unknown
- 2022-03-17 AU AU2022238365A patent/AU2022238365A1/en active Pending
- 2022-03-17 KR KR1020237034937A patent/KR20230158033A/ko active Pending
- 2022-03-17 WO PCT/US2022/020716 patent/WO2022197901A1/en not_active Ceased
- 2022-03-17 EP EP22715444.0A patent/EP4308162A1/en active Pending
- 2022-03-17 JP JP2023554337A patent/JP2024510436A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4308162A1 (en) | 2024-01-24 |
| BR112023018607A2 (pt) | 2023-10-24 |
| JP2024510436A (ja) | 2024-03-07 |
| WO2022197901A1 (en) | 2022-09-22 |
| TW202300156A (zh) | 2023-01-01 |
| AU2022238365A1 (en) | 2023-09-21 |
| US20240245711A1 (en) | 2024-07-25 |
| IL305858A (en) | 2023-11-01 |
| KR20230158033A (ko) | 2023-11-17 |
| CA3213744A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010728A (es) | Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor. | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| BR112021018627A2 (pt) | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia | |
| WO2020205473A8 (en) | Compositions and methods for the treatment of kras associated diseases or disorders | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
| MX2024014467A (es) | Métodos de tratamiento del cáncer con un inhibidor de mtor | |
| JP2021535161A5 (https=) | ||
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| JP2022546456A5 (https=) | ||
| JP2022191405A5 (https=) | ||
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| MX2024003650A (es) | Metodos de dosificacion de inhibidores de transportador apical de acidos biliares dependiente de sodio (asbtis). | |
| WO2023205481A9 (en) | Bavdegalutamide and combinations thereof for use in treating prostate cancer | |
| JPWO2020250915A5 (https=) | ||
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| MX2023005027A (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. | |
| PH12022553376A1 (en) | Acalabrutinib maleate dosage forms | |
| MX2024001266A (es) | 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer. | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| MX2022006071A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| EP4671385A3 (en) | Treatment of squamous cell carcinoma |